Table IV.
Aberrant metaphases | Total aberrations | ||||||
---|---|---|---|---|---|---|---|
Treatment conditions | Dose (µg/ml) | With gaps | Without gaps | With gaps | Without gaps | PP | ER |
Treatment time 6 h, recovery time 18 h, with S9 | |||||||
Vehicle controla | 0.50±0.58 | 0.00±0.00 | 1.25±0.96 | 0.75±0.96 | 0.50±0.58 | 0.25±0.50 | |
PR extract | 0.5 | 0.25±0.50 | 0.00±0.00 | 1.25±0.50 | 1.00±0.00 | 0.50±0.58 | 0.50±0.58 |
5 | 0.75±0.50 | 0.00±0.00 | 1.00±0.82 | 0.25±0.50 | 0.25±0.50 | 0.00±0.00 | |
50 | 0.75±0.50 | 0.00±0.00 | 1.75±0.50 | 1.00±0.00 | 0.50±0.58 | 0.50±0.58 | |
500 | 0.25±0.50 | 0.00±0.00 | 0.50±0.58 | 0.25±0.50 | 0.25±0.50 | 0.00±0.00 | |
1,000 | 0.50±0.58 | 0.00±0.00 | 1.50±1.00 | 1.00±0.82 | 0.75±0.50 | 0.25±0.50 | |
5,000 | 0.50±0.58 | 0.00±0.00 | 1.00±0.00 | 0.50±0.58 | 0.25±0.50 | 0.25±0.50 | |
Cyclophosphamide | 6 | 26.75±3.30b | 23.50±2.38b | 28.75±3.50b | 25.50±2.65b | 0.75±0.50 | 1.25±0.96 |
Treatment time 6 h, recovery time 18 h, without S9 | |||||||
Vehicle controla | 1.00±0.82 | 0.25±0.50 | 2.00±1.41 | 1.25±0.96 | 0.50±0.58 | 0.50±0.58 | |
PR extract | 0.5 | 0.25±0.50 | 0.00±0.00 | 1.00±0.82 | 0.75±0.50 | 0.25±0.50 | 0.50±0.58 |
5 | 0.50±0.58 | 0.00±0.00 | 1.50±0.58 | 1.00±0.82 | 0.50±0.58 | 0.50±0.58 | |
50 | 1.00±0.82 | 0.25±0.50 | 1.50±1.29 | 0.75±0.96 | 0.00±0.00 | 0.50±0.58 | |
500 | 0.25±0.50 | 0.00±0.00 | 0.75±0.50 | 0.50±0.58 | 0.25±0.50 | 0.25±0.50 | |
1,000 | 0.75±0.96 | 0.25±0.50 | 1.50±1.29 | 1.00±0.82 | 0.50±0.58 | 0.25±0.50 | |
5,000 | 0.75±0.96 | 0.25±0.50 | 1.25±0.96 | 0.75±0.50 | 0.25±0.50 | 0.25±0.50 | |
Ethylmethanesulfonate | 800 | 38.50±6.14b | 32.00±4.97b | 39.75±6.55b | 33.25±5.38b | 0.50±0.58 | 0.75±0.50 |
Treatment time 24 h, recovery time 0 h, without S9 | |||||||
Vehicle controla | 1.75±1.71 | 0.75±0.96 | 2.75±1.71 | 1.75±0.96 | 0.25±0.50 | 0.50±0.58 | |
PR extract | 0.5 | 2.25±1.26 | 0.75±0.96 | 3.25±2.22 | 1.75±1.71 | 0.00±0.00 | 0.50±0.58 |
5 | 2.00±1.63 | 1.00±0.82 | 3.25±2.22 | 2.25±1.50 | 0.50±0.58 | 0.50±0.58 | |
50 | 2.00±1.83 | 0.75±0.96 | 3.25±0.96 | 2.00±0.82 | 0.50±0.58 | 0.25±0.50 | |
500 | 1.00±0.82 | 0.25±0.50 | 1.25±0.50 | 0.50±0.58 | 0.25±0.50 | 0.00±0.00 | |
1,000 | 1.25±1.89 | 0.50±1.00 | 3.00±2.83 | 2.25±2.22 | 0.50±1.00 | 0.75±0.96 | |
5,000 | 1.00±0.82 | 0.50±1.00 | 2.00±0.82 | 1.50±0.58 | 0.25±0.50 | 0.25±0.50 | |
Ethylmethanesulfonate | 600 | 56.25±11.41b | 48.25±10.21b | 59.25±13.57b | 51.25±12.50b | 0.75±0.50 | 1.00±0.82 |
Values are expressed as mean ± standard deviation of 100 metaphase cells from quadruple flasks/dose. PR, Persicariae Rhizoma; PP, polyploid; ER, endoreduplication.
Vehicle control, sterile distilled water.
P<0.05 vs. vehicle control by Mann Whitney U test.